Cryosite Valuation
Is CTE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CTE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CTE (A$0.86) is trading below our estimate of fair value (A$1.27)
Significantly Below Fair Value: CTE is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CTE?
Key metric: As CTE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CTE's PE Ratio? | |
|---|---|
| PE Ratio | 22.7x |
| Earnings | AU$1.84m |
| Market Cap | AU$42.95m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.2x |
| Enterprise Value/EBITDA | 16.1x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does CTE's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17x | ||
EZZ EZZ Life Science Holdings | 18.2x | 17.9% | AU$127.5m |
VIT Vitura Health | 16.1x | n/a | AU$56.4m |
VLS Vita Life Sciences | 12.3x | n/a | AU$117.7m |
6662 BioLASCO Taiwan | 21.3x | n/a | NT$904.1m |
CTE Cryosite | 22.7x | n/a | AU$43.0m |
Price-To-Earnings vs Peers: CTE is expensive based on its Price-To-Earnings Ratio (22.7x) compared to the peer average (17x).
Price to Earnings Ratio vs Industry
How does CTE's PE Ratio compare vs other companies in the Global Life Sciences Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CTE is good value based on its Price-To-Earnings Ratio (22.7x) compared to the Global Life Sciences industry average (33.6x).
Price to Earnings Ratio vs Fair Ratio
What is CTE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 22.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CTE's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Little Green Pharma
AU$39.2m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
0%
1Y
6.1%
AVITA Medical
US$339.9m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.92
7D
2.3%
1Y
25.0%
AVITA Medical
US$342.3m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.97
7D
0.3%
1Y
19.6%